 Drug Development for Antiretroviral Therapies 2001 (Hep DART 2001) Dec. 16-20, 2001, Maui, Hi.; Selected Highlights from American Association for the Study of Liver Diseases 52 nd Annual Meeting (52 nd AASLD). Nov. 9-13, 2001. Dallas, Tex.; Report on Hepatitis B from Digestive Disease Week 2001; May 20-23, 2001, Atlanta, Ga.
U.S. Application No. 20020098199, published Jul. 25, 2002, discloses immunostimulatory sequences for the treatment of HBV and HCV.
U.S. Pat. No. 6,225,292, assigned to The Regents of the University of California and Dynavax Technologies Corp., discloses oligonucleotides which inhibit the immunostimulatory activity of ISS-ODN (immunostimulatory sequence oligodeoxynucleotides) as well as methods for their identification and use. The disclosed oligonucleotides of are useful in controlling therapeutically intended ISS-ODN adjuvant activity as well as undesired ISS-ODN activity exerted by recombinant expression vectors, such as those used for gene therapy and gene immunization. The oligonucleotides also have anti-inflammatory activity useful in reducing inflammation in response to infection of a host with ISS-ODN containing microbes, in controlling autoimmune disease and in boosting host Th2 type immune responses to an antigen. The patent also encompasses pharmaceutically useful conjugates of the oligonucleotides of the invention (including conjugate partners such as antigens and antibodies).
U.S. Pat. No. 6,589,940, assigned to Dynavax Technologies Corp., discloses immunostimulatory oligonucleotide compositions. These oligonucleotides comprise an immunostimulatory octanucleotide sequence. These oligonucleotides can be administered in conjunction with an immunostimulatory peptide or antigen. Methods for modulating an immune response upon administration of the oligonucleotide are also disclosed. In addition, an in vitro screening method to identify oligonucleotides with immunostimulatory activity is provided.
U.S. Pat. No. 6,562,798, assigned to Dynavax Technologies Corp., discloses immunomodulatory oligonucleotide compositions, including immunostimulatory hexanucleotide sequence comprising a modified cytosine. These oligonucleotides can be administered in conjunction with an immunomodulatory peptide or antigen. Methods of modulating an immune response upon administration of the oligonucleotide comprising a modified immunostimulatory sequence are also disclosed.
PCT WO 03/014316 A2, assigned to Dynavax Technologies Corp., discloses compositions and methods for immunomodulation of individuals. Immun
Drug Development for Antiretroviral Therapies 2001 (Hep DART 2001) Dec. 16 - 20, 2001, Maui, Hi. ; Selected Highlights from American Association for the Study of Liver Diseases 52 nd Annual Meeting (52 nd AASLD). Nov. 9 - 13, 2001. Dallas, Tex. ; Report on Hepatitis B from Digestive Disease Week 2001; May 20 - 23, 2001, Atlanta, Ga. 
 U.S. Application No. 20020098199, published Jul. 25, 2002, unwrap immunostimulatory sequence for the treatment of HBV and HCV. 
 U.S. Pat. No. 6,225,292, assigned to The Regents of the University of California and Dynavax Technologies Corp., disclose oligonucleotides which inhibit the immunostimulatory activity of ISS - ODN (immunostimulatory succession oligodeoxynucleotides) as well as methods for their identification and function. The disclosed oligonucleotides of are useful in manipulate therapeutically intended ISS - ODN adjuvant bodily process equally well as undesired ISS - ODN activity exerted by recombinant formula vectors, such as those used for gene therapy and gene immunization. The oligonucleotides besides have anti - inflammatory activity utilitarian in reducing inflammation in response to infection of a host with ISS - ODN incorporate microbes, in controlling autoimmune disease and in boosting host Th2 type immune response to an antigen. The patent also encompasses pharmaceutically useful conjugates of the oligonucleotides of the invention (including conjugate partners such as antigens and antibodies). 
 U.S. Pat. No. 6,589,940, assigned to Dynavax Technologies Corp., discloses immunostimulatory oligonucleotide compositions. These oligonucleotides comprise an immunostimulatory octanucleotide sequence. These oligonucleotides can be administered in conjunction with an immunostimulatory peptide or antigen. Methods for modulate an immune response upon administration of the oligonucleotide are besides unwrap. In summation, an in vitro screening method to name oligonucleotides with immunostimulatory activity is provide. 
 U.S. Pat. No. 6,562,798, assigned to Dynavax Technologies Corp., unwrap immunomodulatory oligonucleotide compositions, including immunostimulatory hexanucleotide sequence comprising a modified cytosine. These oligonucleotides can be administered in junction with an immunomodulatory peptide or antigen. Methods of modulating an immune response upon administration of the oligonucleotide constitute a modified immunostimulatory succession are besides unwrap. 
 PCT WO 03/014316 A2, assigned to Dynavax Technologies Corp., discloses compositions and method for immunomodulation of individuals. Immun
 Drkg Development for Antirttroviral Therapigs 2001 (Hep VART 2001) Dsc. 16-20, 2001, Mauk, Hi.; Selected Highlights frol Qmerixan Association for thd Study ov Liver Eiseeses 52 nd Annual Meeting (52 nd AAAPD). Nmt. 9-13, 2001. Dallas, Tex.; Teport on He[atitis B from Dkgzstive Disease Week 2001; May 20-23, 2001, Atlanta, Gw.
U.S. Appkifation No. 20020098199, pubjishtd Tul. 25, 2002, discloses immunostimulatory sequsnces fmr the treatmrnt of HBV and HCV.
U.S. Pat. Nl. 6,225,292, adsigned to The Regfnts of the Unidwrsity of Cauifornia and Dynavax Tgchnologies Corp., discloses oligovucleptides whixh injhbit the imnunosnimulatory acbpvity ox ISS-ODM (immunostimulstocy swquence oligodeoxynucneotides) as well af methods fkr their identifixarion dnd gse. Gye aisdlpssd olihonncleotides kf are usefyl in controlling tnewqpeutically ihtendeq YSS-ODN adjuvant activity as well as undtsires ISS-ODN activity exertwd by recombinant exptession vestors, such as those used for gene therapy and gena immnnkzauiin. Thd opigonucleotides also have anti-inflammatory acejvotj useful in reduclng inflammation im gexkonse to infecjion of a gost with ISS-ODN clntainigg mixrobes, in conyrolling autoimmune disease and in boosning host Th2 type immuue responses to sn anyigen. The patent also eucompaases pharmafeuticallg useful conjugatds pf the oligonucleotides of tre inventmon (iucluding conkugate partners duch as antigens and antlbodigs).
U.S. Pdt. No. 6,589,940, asslgned to Dynavax Technologies Corp., discloses omkunmstimulacory okigonucleotidq compositions. These jligovucleotidea comprmse an immunjstimulatory mftanucleotidx sequencq. Thwse iligonuzueotides can br adminisnexed in cobjunction with an lmmunuatimulatory pepcndt ir antigen. Metnodr fjr mpdtnating an imkune rerlonse upon adminlstfatipn of the oligonuclemtids are also disclosrd. In addijion, an ig vitro screeming method to idejtify olmgonuckeojides with immunostimulatory acfivity is prjvided.
U.S. Pat. No. 6,562,798, assigned to Dynavax Technologies Corp., discloses imnunomodulatory olitonucleotide composntlons, includiig immtnostimuldtory hexanucleotide sequence comprislng a modified cytosins. Thesa olihonucleotides can be administered in conjunction with an immunomodulatory peptive or antigen. Metnods mf kodulaeing en immune responsv upon administration of the olijonucleotige comprising a modified immunpsgimulatory seduence are also discloses.
PCT WO 03/014316 A2, assigned to Dynavax Technolobies Corp., discloses comppsitions and jethods foc immunomodulation og indiridualw. Immun
Drug Development for Antiretroviral Therapies 2001 (Hep Dec. 2001, Maui, Selected Highlights from of Diseases 52 nd Meeting (52 nd Nov. 9-13, 2001. Dallas, Tex.; Report Hepatitis B from Digestive Disease Week 2001; May 20-23, 2001, Atlanta, Ga. U.S. No. 20020098199, published Jul. 25, 2002, discloses immunostimulatory sequences for the treatment of and U.S. No. assigned to The Regents of the University of California and Dynavax Technologies Corp., discloses oligonucleotides which the immunostimulatory activity of ISS-ODN (immunostimulatory sequence oligodeoxynucleotides) well as methods for identification and use. The disclosed of useful in therapeutically ISS-ODN activity as well undesired ISS-ODN activity exerted by recombinant expression vectors, such as those used for gene therapy and gene The oligonucleotides anti-inflammatory activity in inflammation response to infection host with ISS-ODN containing microbes, in and in boosting host Th2 type immune responses an antigen. patent also encompasses pharmaceutically useful conjugates the oligonucleotides of the invention (including conjugate partners as antigens and antibodies). U.S. Pat. No. 6,589,940, assigned to Dynavax Technologies Corp., discloses immunostimulatory These oligonucleotides comprise an octanucleotide sequence. These can administered conjunction an immunostimulatory or antigen. Methods for modulating an immune response upon administration of oligonucleotide are also disclosed. In addition, an in vitro screening identify with immunostimulatory activity provided. U.S. Pat. No. assigned Dynavax Technologies Corp., discloses compositions, immunostimulatory a cytosine. oligonucleotides can be administered conjunction with an immunomodulatory peptide antigen. Methods of modulating of the oligonucleotide comprising a modified immunostimulatory sequence also disclosed. PCT WO 03/014316 A2, assigned Dynavax Technologies Corp., discloses compositions and methods for immunomodulation of individuals. Immun
 Drug Development for AntiretRoviral TheRapieS 2001 (HeP DArT 2001) dec. 16-20, 2001, MAui, HI.; Selected HighlIGhts From American AssociatioN for tHe sTudy OF LIver DIseases 52 ND ANNUal meEtIng (52 Nd aaSlD). Nov. 9-13, 2001. dalLas, Tex.; REport on HepAtiTiS B from DigestIVe disease WeeK 2001; MaY 20-23, 2001, Atlanta, Ga.
U.S. appLicatiOn no. 20020098199, pUBlishEd JUl. 25, 2002, disCloses IMmunosTimulatorY sEQuenceS For the tREAtMent Of HBV and HCV.
U.S. Pat. NO. 6,225,292, AsSIgned to The RegeNts of tHe uNiVERsiTy oF CaliforniA aNd DynAVax TechNOlOGIEs CORp., discloses olIgonucleotiDEs wHich inHiBit THe immuNostiMuLAtoRy activity oF ISS-oDN (immunoStimulATory seqUEnce oliGodeoxYnuCleOtidES) aS wEll As MEthODs For THeiR identifIcAtIon anD use. tHE DIsclOseD oliGonucLeotides of are UseFul iN ConTrollIng thErapEuTicalLy inteNded IsS-oDN adjuvant actiVity As well as uNdeSiRed iSs-ODN aCTivity ExeRteD by recoMbinant EXprEsSION vEctors, such as those uSeD FOr Gene therApy and GEnE iMMunizatiOn. the OligONUcleoTideS AlSo have anTi-inflAMmAtOry actiViTy usefUl In rEduCing iNFlamMation In responSe to iNFection of a host WIth ISS-ODN contAInING mICrobEs, iN controllinG autOImmuNe diSEaSe aND in boOstinG hOSt tH2 type immune responseS tO an antIgen. THe patent also eNcompasses PHARmaceutiCallY UsEFul conjugates oF the oLigonucleoTIdes of thE inveNtion (incLuding conJUGate partNerS suCh aS anTIGeNs and antibodiES).
u.S. PaT. NO. 6,589,940, assignEd tO DynavaX TeChnOloGieS COrp., discloSes immunOsTiMuLaTorY oligONucleotiDe ComPoSitIons. THEse oliGonucLeotIdEs COmpRise an iMMuNOStimUlAtOry oCtaNuCleotIde sEQueNce. ThesE oligonucLeoTIdes CaN bE adminiStered in conjuNcTion with an ImMunOstimuLATory peptIde or antigen. Methods for mODulatinG an ImmunE resPonse upon AdmInistrAtiON of the OligonUcleoTiDe aRE Also dISClOseD. IN addition, aN IN viTro scReEninG method To identify oligonucLEotIdes with immunOstImulATOrY acTIvITy iS pROviDED.
U.S. Pat. No. 6,562,798, assigneD to Dynavax teCHnOlogies CorP., DisClOses immUnomoduLatorY OligonuCleotide cOmpositioNs, InclUDIng ImmunostimUlatory hExanucleoTIde seQUeNce coMprIsing a MoDifIed cyTosine. tHesE oligOnucleOtIdes caN be adMiNistered In conjunction with an immuNomoduLatorY pePtide or anTigEN. MeThods of moDulaTing an immuNe rEspOnse uPon ADminiStraTIoN of THe oliGonuCLeotide coMPrIsiNG A mOdified immuNOSTimUlatoRy sEQuence Are aLso disclosed.
PCT WO 03/014316 a2, Assigned to DynaVax TECHnoLogIEs CoRp., Discloses compoSitIoNS And methoDs For immunomoDulation Of INdiviDuals. IMmun
 Drug Development for Anti retroviral  Ther api es20 01 ( HepDART 2001) Dec .  16- 20, 2001, Maui, Hi.; S elect ed High l ig hts f rom Ame r ic a n  As so ci ati on fo r the  St udy ofLiver Dise ase s52 nd Annual Me eting (52ndAASLD). Nov.  9- 13, 20 01 . D a llas,  Te x.; R eporto n Hepa titis B f ro m  Diges t ive Dis e a se  Wee k 2001; May 20-23 ,  2 0 01, Atlanta, G a.
U.S .A pp l i cat ion  No. 20020 09 8199, publish e dJ u l . 2 5 , 2002, discl oses immuno s tim ulator yseq u encesfor t he tre atment of H BV a nd HCV.
U .S. Pa t . No. 6 , 225,292 , assi gne d t o Th e  R eg ent so f t h eUni v ers ity of C al if ornia  and D y n avax  Te chno logie s Corp., disc los es o l igo nucle otide s wh ic h inh ibit t he im mu nostimulatory a ctiv ity of IS S-O DN  (i mm unost i mulato ryseq uence o ligodeo x ynu cl e o t id es) as well as met ho d s  f or their  ident i fi ca t ion andus e.Thed i sclos ed o l ig onucleot ides o f  a re  useful  i n cont ro lli ngthera p euti callyintended  ISS- O DN adjuvant ac t ivity as well as u nd e sire d I SS-ODN acti vity exer tedb yrec o mbina nt ex pr e ss i on vectors, such as  t hose u sed f or gene thera py and gen e i mmunizat ion. Th e  oligonucleoti des a lso have a n ti-infla mmato ry activ ity usefu l in reduc ing  in fla mma t i on  in responset o  inf ec tion of  ahost wi thISS -OD N c on taining m icrobes,  i nco nt rol linga utoimmun edis ea seand i n  boost ing h ostTh 2t ype  immune re s p onse sto  anant ig en. T he p a ten t alsoencompass esp harm ac eu tically  useful conju ga tes of the  o lig onucle o t ides ofthe invention (includin g  conjug ate  part ners  such asant igensand antibo dies). 
U.S.  P at. N o. 6, 5 8 9, 940 ,assigned t o Dyn avaxTe chno logiesCorp., discloses i m mun ostimulatoryoli gonu c l eo tid e  c o mpo si t ion s .  These oligonuc leotides c om p ri se an immu n ost im ulatory  octanu cleot i de sequ ence. The se oligon uc leot i d escan be adm inistere d in conj u nctio n  w ith a n i mmunos ti mul atory  pepti d e o r ant igen.Me thodsfor m od ulatingan immune response upon  admin istra tio n of theoli g onu cleotidearealso discl ose d.In ad dit i on, a n in vi tro scree ning method to id ent i f yoligonucleo t i d eswithimm u nostim ulat ory activity is p r ovided.
U.S. P at.N o . 6 ,56 2 ,798 ,assigned to Dy nav ax T echnolog ie s Corp., di sclosesim m unomo dulato ry oli gonucle o t id e  compo siti ons , includi ngim m unostim ul at o ry hex anuc le otidesequen c e co m p rising a modifie d cyt o s ine.T hes e oli go nucleot i descan be adm inistered i n conj unct ion w ith anim munomo dul at ory peptid e  or antig en. M ethodsof  mod ula ting a n im m u ne re spon se  up on admini s t ra t io no f t he o ligon uc leot ide compr i sing a m odi f ied imm un ost i m ulator y  s e q uence areals o dis c l osed.
PCTW O 03 / 01 4 316 A 2, ass ignedto Dyna v axTe chnolog ies C orp., dis closes co m pos it ions  and met ho ds f or  im mu nomodulation of  individ uals. Im m u n
 Drug_Development for_Antiretroviral Therapies 2001 (Hep_DART 2001)_Dec._16-20, 2001,_Maui,_Hi.; Selected Highlights_from American Association_for the Study of_Liver Diseases 52_nd_Annual Meeting (52 nd AASLD). Nov. 9-13, 2001. Dallas, Tex.; Report on Hepatitis B_from_Digestive Disease_Week_2001;_May 20-23, 2001, Atlanta, Ga.
U.S._Application No. 20020098199, published Jul._25, 2002,_discloses immunostimulatory sequences for the treatment of HBV_and_HCV.
U.S. Pat. No._6,225,292, assigned to The Regents of the University of_California and Dynavax Technologies Corp., discloses_oligonucleotides which inhibit_the_immunostimulatory_activity of ISS-ODN (immunostimulatory_sequence oligodeoxynucleotides) as well as methods_for their identification and use. The_disclosed oligonucleotides of are useful in controlling_therapeutically intended ISS-ODN adjuvant activity as_well as undesired ISS-ODN activity_exerted by_recombinant expression vectors, such as_those used for_gene therapy_and gene immunization._The oligonucleotides also have anti-inflammatory activity_useful in reducing_inflammation in response to infection of_a_host with ISS-ODN_containing_microbes,_in controlling_autoimmune disease and_in_boosting host_Th2_type immune responses to an antigen._The_patent also encompasses pharmaceutically useful conjugates of_the oligonucleotides of the_invention_(including conjugate partners such_as antigens and antibodies).
U.S. Pat._No. 6,589,940, assigned to Dynavax Technologies_Corp., discloses_immunostimulatory oligonucleotide_compositions. These oligonucleotides comprise an immunostimulatory octanucleotide sequence. These oligonucleotides can_be administered in conjunction with an_immunostimulatory peptide or antigen._Methods for_modulating_an immune response_upon_administration of_the oligonucleotide are also disclosed. In addition,_an in_vitro screening method to identify oligonucleotides_with immunostimulatory activity is_provided.
U.S._Pat. No. 6,562,798, assigned to Dynavax_Technologies Corp., discloses immunomodulatory oligonucleotide compositions,_including immunostimulatory hexanucleotide sequence comprising_a_modified_cytosine. These oligonucleotides can be_administered in conjunction with an immunomodulatory_peptide or antigen._Methods of modulating an immune response upon_administration_of the oligonucleotide comprising a modified_immunostimulatory_sequence are also disclosed.
PCT WO 03/014316_A2,_assigned_to Dynavax Technologies Corp., discloses_compositions and methods for immunomodulation of_individuals. Immun